MAIA Biotechnology, Inc. (MAIA)
(Delayed Data from AMEX)
$2.94 USD
+0.26 (9.70%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $3.01 +0.07 (2.38%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth F Momentum F VGM
Brokerage Reports
0 items in cart
MAIA Biotechnology, Inc. [MAIA]
Reports for Purchase
Showing records 1 - 9 ( 9 total )
Company: MAIA Biotechnology, Inc.
Industry: Medical - Biomedical and Genetics
THIO-101 Advancing in Phase 2 NSCLC Trials With Multiple Upcoming Milestones
Provider: Diamond Equity Research LLC
Analyst: DIAMOND H
Company: MAIA Biotechnology, Inc.
Industry: Medical - Biomedical and Genetics
Strategic Advancements in Oncology with THIO-101 and Successful Capital Raise
Provider: Diamond Equity Research LLC
Analyst: DIAMOND H
Company: MAIA Biotechnology, Inc.
Industry: Medical - Biomedical and Genetics
Showcases Encouraging Efficacy Profile in Preliminary Readout Compared to Standard of Care
Provider: Diamond Equity Research LLC
Analyst: DIAMOND H
Company: MAIA Biotechnology, Inc.
Industry: Medical - Biomedical and Genetics
Q2 2023 Financial Results Reflect Pipeline Advancements
Provider: Diamond Equity Research LLC
Analyst: DIAMOND H
Company: MAIA Biotechnology, Inc.
Industry: Medical - Biomedical and Genetics
Encouraging THIO-101 Phase 2 Trial Data and Second Patent Application Filed
Provider: Diamond Equity Research LLC
Analyst: DIAMOND H
Company: MAIA Biotechnology, Inc.
Industry: Medical - Biomedical and Genetics
Promising Efficacy and Safety in NSCLC and HCC Reaffirms Potential
Provider: Diamond Equity Research LLC
Analyst: DIAMOND H
Company: MAIA Biotechnology, Inc.
Industry: Medical - Biomedical and Genetics
FY 2022 Financial Results Update and Operational Highlights
Provider: Diamond Equity Research LLC
Analyst: DIAMOND H
Company: MAIA Biotechnology, Inc.
Industry: Medical - Biomedical and Genetics
Progress Across Multiple Clinical and Pre-Clinical Pipeline Candidates
Provider: Diamond Equity Research LLC
Analyst: DIAMOND H
Company: MAIA Biotechnology, Inc.
Industry: Medical - Biomedical and Genetics
Initiation Report-Pan-cancer Therapeutic Applications with Potential to Overcome Therapeutic Resistance
Provider: Diamond Equity Research LLC
Analyst: DIAMOND H
|